Box 11.1 Monitoring HIV drug resistance
Consolidated ARV guidelines, June 2013
HIV drug resistance poses a significant threat to the success of national HIV programmes. Drug resistance results in more rapid virological failure among people receiving first-line regimens and increases the need for second-line regimens, which may be associated with greater toxicity, adverse events, poorer adherence and higher costs. Drug resistance may also affect the ability to prevent HIV transmission using ARV-based pre- or post-exposure prophylaxis or topical microbicides.
Surveillance of drug resistance should be an integral component of national HIV programmes. Surveillance data should inform the selection of first- and second-line regimens for ART, as well as ARV drugs for PMTCT, to optimize treatment outcomes within a public health approach.
WHO and its partners have developed a standardized and complementary assessment strategy to be implemented by countries, for both adult and paediatric populations, with the following components.
Monitoring early warning indicators for HIV drug resistance. Early warning indicators use existing clinic and pharmacy records to assess the factors associated with the emergence of HIV drug resistance at the level of ART programmes and clinics. These factors include ART prescribing practices; drug supply continuity; adherence to ARV drug regimens measured by on-time pick-up of ARV drugs; retention in care; and viral load suppression, when available. The monitoring of early warning indicators should be integrated into a country’s monitoring and evaluation system and provides the information needed to address practices that may lead to poor outcomes and HIV drug resistance.
Surveys to monitor acquired HIV drug resistance and associated factors in populations receiving ART. The WHO generic protocol for monitoring acquired HIV drug resistance uses a standardized survey methodology to assess population-level virological suppression at the national level and the emergence of HIV drug resistance among populations receiving treatment. Performed regularly at representative sites, these surveys provide evidence for action at the programme and clinic level to minimize HIV drug resistance. They also provide evidence to optimize the selection of first- and second-line ART regimens.
Surveys to monitor pre-treatment HIV drug resistance. The WHO generic protocol for surveillance of pre-treatment HIV drug resistance provides a nationally representative estimate of HIV drug resistance in populations initiating therapy. Performed regularly at representative ART clinics, these surveys support national, regional and global decision-making regarding the choice of first-line regimens.
Surveillance of transmitted HIV drug resistance among individuals recently infected with HIV. The WHO generic protocol for surveillance of transmitted HIV drug resistance provides estimates of transmitted HIV drug resistance in recently infected populations, and the results should contribute to ART policy decisions, including guidelines on ART regimens and HIV prophylaxis.
Surveillance of HIV drug resistance among infants under 18 months of age. The WHO generic protocol for surveillance of HIV drug resistance among children under 18 months of age can provide estimates of national prevalence of HIV drug resistance among infants diagnosed with HIV infection through early infant diagnosis testing. The results assess differences in HIV drug resistance prevalence between populations exposed to ARV drugs for PMTCT and those with unknown exposure to support the selection of optimal first-line ART for this population.
National strategies for assessing HIV drug resistance should be developed and routinely implemented as part of comprehensive HIV treatment programmes.